Anti-estrogen cross resistance in human breast cancer

被引:0
|
作者
De Soto, Joseph A.
Fryar, Elizabeth B.
Grissom, Felix E.
Southerland, William M.
Green, Sidney
Bowen, Donnell
机构
来源
Chemist | 2006年 / 83卷 / 02期
关键词
Diseases - Cancer cells;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction: Recently, the STAR study showed that raloxifene works at least as well as tamoxifen in preventing breast cancer. It is of interest to know whether raloxifene may be used in the treatment of breast cancer and whether it would be effective in those who have developed resistance to other anti-estrogens. Methods: Estrogen receptor positive (er+) and negative (er-) breast cancer cells were exposed to tamoxifen, raloxifene or faslodex for 48 hours and the efficacy and potency of these drugs determined. MCF-7 breast cancer sub-lines lines resistant to tamoxifen (TAMR), raloxifene (RALR) or faslodex (FASR) were developed and used to determine cross-resistance among anti-estrogens Results: The efficacy of tamoxifen, raloxifene, and faslodex in inhibiting the proliferation of MCF-7 estrogen receptor positive er+ breast cancer were equivalent though theirs potencies differed. However, anti-estrogens were unable to inhibit the growth of er-breast cancer cells. TAMR sub-lines were resistant to raloxifene and faslodex, while FASR sub-lines were resistant to tamoxifen and raloxifene. RALR sub-lines however, were sensitive to treatment with tamoxifen in vitro and in vivo. Conclusions: The anti-estrogens tamoxifen, raloxifene and faslodex are equally efficacious in inhibiting breast cancer growth in er+ tumors. RALR sub-lines are sensitive to tamoxifen treatment. © Copyright 2007. American Institute of Chemists, Inc.
引用
收藏
相关论文
共 50 条
  • [31] Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
    Simoes, Bruno M.
    O'Brien, Ciara S.
    Eyre, Rachel
    Silva, Andreia
    Yu, Ling
    Sarmiento-Castro, Aida
    Alferez, Denis G.
    Spence, Kath
    Santiago-Gomez, Angelica
    Chemi, Francesca
    Acar, Ahmet
    Gandhi, Ashu
    Howell, Anthony
    Brennan, Keith
    Ryden, Lisa
    Catalano, Stefania
    Ando, Sebastiano
    Gee, Julia
    Ucar, Ahmet
    Sims, Andrew H.
    Marangoni, Elisabetta
    Farnie, Gillian
    Landberg, Goeran
    Howell, Sacha J.
    Clarke, Robert B.
    CELL REPORTS, 2015, 12 (12): : 1968 - 1977
  • [32] ESTROGEN AND ANTI-ESTROGEN EFFECTS ON THE GROWTH OF HUMAN OVARIAN-CANCER (HOC) INVITRO
    NASH, JD
    HAMILTON, TC
    SMYTH, JF
    FOJO, AT
    OZOLS, RF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 242 - 242
  • [33] AN UPDATE ON THE PROPERTIES OF ANTI-ESTROGEN BINDING-SITES IN HUMAN-BREAST CANCER-CELLS
    SUTHERLAND, RL
    WATTS, CKW
    MURPHY, LC
    BREAST CANCER RESEARCH AND TREATMENT, 1983, 3 (03) : 305 - 305
  • [34] Anti-estrogen Therapy and Fertility Preservation in Premenopausal Breast Cancer Patients: a Review
    Marcela Mazo Canola
    Virginia G. Kaklamani
    Current Breast Cancer Reports, 2022, 14 : 29 - 36
  • [35] HISTOLOGIC CORRELATES OF ANTI-ESTROGEN RECEPTOR ANTIBODY LOCALIZATION IN BREAST-CANCER
    SZABO, E
    COX, EB
    FLOWERS, JL
    MILLER, L
    MCCARTY, KS
    GEORGIADE, GS
    MCCARTY, KS
    BREAST CANCER RESEARCH AND TREATMENT, 1985, 6 (02) : 183 - 183
  • [36] Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes
    Guo, Jimin
    Canaff, Lucie
    Rajadurai, Charles Vincent
    Fils-Aime, Nadege
    Tian, Jun
    Dai, Meiou
    Korah, Juliana
    Villatoro, Manuel
    Park, Morag
    Ali, Suhad
    Lebrun, Jean-Jacques
    BREAST CANCER RESEARCH, 2014, 16 (06):
  • [37] Anti-estrogen Therapy and Fertility Preservation in Premenopausal Breast Cancer Patients: a Review
    Mazo Canola, Marcela
    Kaklamani, Virginia G.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (02) : 29 - 36
  • [38] Quantitative Progesterone Receptor Expression and Efficacy of Anti-estrogen Therapy in Breast Cancer
    Luoh, Shiuh-Wen
    Ramsey, Betsy
    Park, Byung
    Keenan, Edward
    BREAST JOURNAL, 2014, 20 (01): : 46 - 52
  • [39] Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes
    Jimin Guo
    Lucie Canaff
    Charles Vincent Rajadurai
    Nadège Fils-Aimé
    Jun Tian
    Meiou Dai
    Juliana Korah
    Manuel Villatoro
    Morag Park
    Suhad Ali
    Jean-Jacques Lebrun
    Breast Cancer Research, 16
  • [40] Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells
    Martinez-Outschoorn, Ubaldo E.
    Goldberg, Allison
    Lin, Zhao
    Ko, Ying-Hui
    Flomenberg, Neal
    Wang, Chenguang
    Pavlides, Stephanos
    Pestell, Richard G.
    Howell, Anthony
    Sotgia, Federica
    Lisanti, Michael P.
    CANCER BIOLOGY & THERAPY, 2011, 12 (10) : 924 - 938